Hepatoportal cholangiocarcinoma Disease introduction: Hepatoportal cholangiocarcinoma, also known as Klatskin’s tumor, is a common malignant tumor of biliary system. It is a common malignant tumor in the biliary system, and its special site of occurrence, infiltrative growth and close relationship with blood vessels in the hepatoportal area make surgical resection extremely difficult. For a long time, hepatoportal cholangiocarcinoma was considered to be a tumor that could not be radically resected. In the past 20 years, with the progress of imaging and surgical techniques, the diagnosis and treatment of hepatoportal bile duct cancer have made significant progress, the surgical resection rate has been gradually increased, and the survival rate has been significantly improved. Clinical manifestations: Early stage has no specific clinical manifestations, painless jaundice is the earliest and the most important symptom of hilar cholangiocarcinoma, which is progressively aggravated, accompanied by nausea, vomiting, emaciation, patients with deep yellow urine, light stool or even clay-colored, etc. Often, it produces the manifestations of obstructive cholangitis, such as chills, fever with liver function damage. Diagnosis: Relying on ultrasound, CT, MRCP, PTC, ERCP and other imaging examinations, combined with serum tumor markers, such as CEA, CA199, CA125, etc. can make a clear diagnosis. Enhanced CT can show the relationship between the tumor and the surrounding blood vessels; MRCP can clearly show the whole bile ducts, which is more instructive for clinical staging; PTC can directly show the location of the tumor and the range of the affected hepatic ducts, and can be used to reduce the yellow color by PTCD before surgery. Treatment: Hepatoportal cholangiocarcinoma can only be completely cured by radical resection. Radical resection includes resection of extrahepatic bile ducts, skeletonized clearance of hepatoduodenal lymph nodes and bilioenteric R-Y anastomosis, and resection of one side of the hepatic lobe and caudate lobe for hilar cholangiocarcinoma of Bismuth III or above, and liver transplantation can be considered for hilar cholangiocarcinoma of type IV. For cases that cannot be resected, biliary stent internal drainage or intrahepatic bile duct puncture external drainage can be chosen.